Kim Ji Hye, Kim Young Soo, Kim Tae In, Li Wei, Mun Jeong-Geon, Jeon Hee Dong, Kee Ji-Ye, Choi Jang-Gi, Chung Hwan-Suck
Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), Dong-gu, Daegu 41062, Korea.
Department of Oriental Pharmacy, College of Pharmacy, Wonkwang-Oriental Medicines Research Institute, Wonkwang University, 460 Iksandae-ro, Iksan, Jeonbuk 54538, Korea.
Foods. 2020 Nov 2;9(11):1590. doi: 10.3390/foods9111590.
Miquel () is a unripen fruit of black raspberry native to eastern Asia. It is used as traditional oriental medicine and supplementary foods for centuries. Previous studies have shown that the extract (RCE) and its main constitute ellagic acid possess diverse biological activities. However, the effects of RCE on antitumor immunity and T cell function were not fully understood. The present study describes the anti-tumor effect of RCE in humanized PD-1 mice by blocking PD-1/PD-L1 interaction. Competitive enzyme-linked immunosorbent assay (ELISA) and pull down assay were performed to elucidate the binding properties of RCE in vitro. Cellular PD-1/PD-L1 blockade activities were measured by T cell receptor (TCR)-induced nuclear factor of activated T cells-luciferase activity in co-cultured cell models with PD-1/NFAT Jurkat and PD-L1/aAPC CHO-K1 cells. The in vivo efficacy of RCE was confirmed in humanized PD-1 mice bearing MC38 colorectal tumor. RCE and ellagic acid dose-dependently block the binding of PD-1 to PD-L1. Moreover, oral administration of RCE showed the potent anti-tumor activity similar to anti-PD-1 antibody. The present study suggests that RCE possesses potent anti-tumor effect via PD-1/PD-L1 blockade, and ellagic acid is the main compound in RCE. Thus, we provide new aspects of RCE as an immunotherapeutic agent.
米奎尔(Miquel)是一种原产于东亚的未成熟黑莓果实。几个世纪以来,它一直被用作传统的东方药物和补充食品。先前的研究表明,提取物(RCE)及其主要成分鞣花酸具有多种生物活性。然而,RCE对抗肿瘤免疫和T细胞功能的影响尚未完全了解。本研究描述了RCE通过阻断PD-1/PD-L1相互作用在人源化PD-1小鼠中的抗肿瘤作用。采用竞争性酶联免疫吸附测定(ELISA)和下拉测定法在体外阐明RCE的结合特性。通过在与PD-1/NFAT Jurkat和PD-L1/aAPC CHO-K1细胞共培养的细胞模型中,用T细胞受体(TCR)诱导的活化T细胞核因子-荧光素酶活性来测量细胞PD-1/PD-L1阻断活性。在携带MC38结肠肿瘤的人源化PD-1小鼠中证实了RCE的体内疗效。RCE和鞣花酸剂量依赖性地阻断PD-1与PD-L1的结合。此外,口服RCE显示出与抗PD-1抗体相似的强效抗肿瘤活性。本研究表明,RCE通过阻断PD-1/PD-L1具有强效抗肿瘤作用,鞣花酸是RCE中的主要化合物。因此,我们为RCE作为一种免疫治疗剂提供了新的视角。